SCHEMBL6086097

SCHEMBL6086097

CC(=O)Nc1ccc(-c2n[nH]cc2-c2nc3cc(C(C)(C)C)ccc3o2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.52
RAB9A P51151 7/20 0.52
POLB P06746 3/20 0.52
CASP3 P42574 3/20 0.52
SENP7 Q9BQF6 3/20 0.52
TDP1 Q9NUW8 1/20 0.52
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
MAPT P10636 5/20 0.50
HPGD P15428 2/20 0.50
NFKB1 P19838 2/20 0.50
NFKB2 Q00653 2/20 0.50
RELA Q04206 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TP53 P04637 2/20 0.50
SENP8 Q96LD8 2/20 0.50
SENP6 Q9GZR1 2/20 0.50
UTRN P46939 1/20 0.50
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085115 0.91 CETP (0.47) NPC1RAB9APOLBKDM4EALDH1A1
SCHEMBL6086007 0.91 AGPAT2 (0.48) NPC1RAB9APOLBCASP3SENP7
SCHEMBL6084919 0.90 MAPT (0.56) NPC1RAB9APOLBKDM4EALDH1A1
SCHEMBL6085453 0.89 MAPT (0.49) NPC1RAB9APOLBTDP1KDM4E
SCHEMBL6085356 0.88 RXFP1 (0.44) NPC1RAB9ACASP3SENP7KDM4E
SCHEMBL6086312 0.88 MAPT (0.52) NPC1RAB9APOLBTDP1SMN1; SMN2
SCHEMBL6085392 0.88 CETP (0.45) NPC1RAB9APOLBCASP3SENP7
SCHEMBL6085988 0.87 CETP (0.44) NPC1RAB9APOLBCASP3SENP7
SCHEMBL6084904 0.87 NPC1 (0.51) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL6085057 0.87 NPC1 (0.51) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 NPC1 4031/4885RAB9A 2584/4885POLB 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.